[(3aR,4S,6Z,10Z,11aR)-10-(hydroxymethyl)-6-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 3,4-dihydroxy-2-methylidenebutanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(3aR,4S,6Z,10Z,11aR)-10-(hydroxymethyl)-6-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 3,4-dihydroxy-2-methylidenebutanoate
• 化学式: C₂₀H₂₆O₇
• 分子量: 378.4
• InChiKey: ZTDFZLVUIVPZDU-NDDNEAKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• TREATMENT OF NEUROBLASTOMA WITH HISTONE DEACETYLASE INHIBITORS
  申请人：Acetylon Pharmaceuticals Inc.

  公开号：US20160339022A1

  公开（公告）日：2016-11-24

  Provided herein are combinations comprising an HDAC inhibitor and retinoic acid for the treatment of neuroblastoma in a subject in need thereof. Also provided herein are methods for treating neuroblastoma in a subject in need thereof, comprising administering to the subject an effective amount of the above HDAC inhibitor or combination, comprising administering to the subject in need thereof an effective amount of the above HDAC inhibitor or combination. Also provided herein is a method for predicting whether a neuroblastoma patient will respond to treatment with a combination comprising an HDAC inhibitor and retinoic acid.

  本文提供了一种包括HDAC抑制剂和维甲酸的组合物，用于治疗需要治疗的神经母细胞瘤患者。本文还提供了一种治疗神经母细胞瘤的方法，包括向需要治疗的患者施用上述HDAC抑制剂或组合物的有效剂量。本文还提供了一种预测神经母细胞瘤患者是否对包括HDAC抑制剂和维甲酸的组合物治疗有反应的方法。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Non-steroidal farnesoid x receptor modulators and methods for the use thereof
  申请人：Downes R Michael

  公开号：US20060128764A1

  公开（公告）日：2006-06-15

  The efficient regulation of cholesterol synthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. In accordance with the present invention, the identification of novel potent FXR activators is described. Two derivatives of invention compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds are useful as chemical tools to further define the physiological role of FXR as well as therapeutic leads for the treatment of diseases linked to cholesterol, bile acids and their metabolism and homeostasis.

  胆固醇合成、代谢、获取和运输的高效调节是脂类稳态的重要组成部分。法尼索德X受体（FXR）是胆固醇代谢的主要产物——胆汁酸的转录传感器。因此，开发有效、选择性、小分子的FXR激动剂、部分激动剂和拮抗剂将是进一步解析FXR生理学的重要一步。根据本发明，描述了新型有效的FXR激动剂的鉴定。发明化合物的两个衍生物，携带了联苯或联苯醚基团，包含了迄今为止在细胞基础实验中报道的最有效的FXR激动剂。这些化合物可用作化学工具，进一步定义FXR的生理作用，以及治疗与胆固醇、胆汁酸及其代谢和稳态相关的疾病的治疗前导化合物。
• Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
  申请人：Ajami M. Alfred

  公开号：US20080108641A1

  公开（公告）日：2008-05-08

  Compounds of formula (I) and a method of treating a patient suffering from an inflammatory and/or demyelinating disorders, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided therein.

  公式（I）的化合物及治疗患有炎症和/或脱髓鞘性疾病的患者的方法，包括向该患者施用公式（I）的化合物或其药学上可接受的盐的治疗有效量。其中提供了变量的定义。
• Primers for synthesising full-length cDNA and their use
  申请人：Helix Research Institute

  公开号：EP1074617A2

  公开（公告）日：2001-02-07

  Primers for synthesizing full-length cDNAs and their use are provided. 5602 cDNA encoding a human protein has been isolated and nucleotide sequences of 5'-, and 3' -ends of the cDNA have been determined. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA of the present invention containing the translation start site provides information useful for analyzing the functions of the protein.

  提供了合成全长 cDNA 的引物及其用途。 已分离出编码一种人类蛋白质的 5602 cDNA，并确定了该 cDNA 的 5'端和 3'端核苷酸序列。此外，还提供了合成全长 cDNA 的引物，以明确 cDNA 所编码蛋白质的功能。本发明的全长 cDNA 含有翻译起始位点，为分析蛋白质的功能提供了有用的信息。